Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells
Yuan Fang, Yajun Zhang, Chuanxin Guo, Chumeng Chen, Haixia Gao, Xiumei Zhou, Tao Liu, Qijun Qian
Abstract
CAR T cells showed increased secretion of anti-PD-1 antibody under control of the chimeric promoter CIFT. pS-CIFT-αPD-1/CAR T also had similar or lower PD-1 expression, higher levels of T cell activation, more release of IFN-γ, and better antitumor activity specifically against mesothelin-positive and PD-1 ligand 1 (PD-L1)-positive cell lines. The chimeric promoter may be a promising strategy to manipulate the content of immune checkpoint inhibitors or other proteins in future therapeutic approaches for cancer treatment.
Topics & Concepts
AntibodyImmune systemChimeric antigen receptorCancer researchCell biologyChemistryBiologyT cellImmunologyCAR-T cell therapy research